Early trial of tazemetostat for tough T-Cell lymphoma halted after just 6 patients
NCT ID NCT05983965
First seen Nov 01, 2025 · Last updated Jun 18, 2026 · Updated 35 times
Summary
This early-phase study tested the safety of a drug called tazemetostat in people with a type of blood cancer called peripheral T-cell lymphoma that had returned or stopped responding to other treatments. Only 6 participants were enrolled before the study was stopped early. The goal was to find a safe dose by watching for side effects in the first month.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERIPHERAL T CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.